Arciniegas Calle, M.C.; Sandhu, N.P.; Xia, H.; Cha, S.S.; Pellikka, P.A.; Ye, Z.; Herrmann, J.; Villarraga, H.R. Two‐Dimensional Speckle Tracking Echocardiography Predicts Early Subclinical Cardiotoxicity Associated with Anthracycline‐Trastuzumab Chemotherapy in Patients with Breast Cancer. BMC Cancer 2018, 18, 1037, doi:10.1186/s12885‐018‐4935‐z.
Santoro, C.; Arpino, G.; Esposito, R.; Lembo, M.; Paciolla, I.; Cardalesi, C.; de Simone, G.; Trimarco, B.; De Placido, S.; Galderisi, M. 2D and 3D Strain for Detection of Subclinical Anthracycline Cardiotoxicity in Breast Cancer Patients: A Balance with Feasibility. Eur. Heart J. Cardiovasc. Imaging 2017, 18, 930–936, doi:10.1093/ehjci/jex033.
Jain, K.K.; Casper, E.S.; Geller, N.L.; Hakes, T.B.; Kaufman, R.J.; Currie, V.; Schwartz, W.; Cassidy, C.; Petroni, G.R.; Young, C.W. A Prospective Randomized Comparison of Epirubicin and Doxorubicin in Patients with Advanced Breast Cancer. J. Clin. Oncol. 1985, 3, 818–826, doi:10.1200/JCO.1985.3.6.818.
Hortobagyi, G.N.; Yap, H.Y.; Kau, S.W.; Fraschini, G.; Ewer, M.S.; Chawla, S.P.; Benjamin, R.S. A Comparative Study of Doxorubicin and Epirubicin in Patients with Metastatic Breast Cancer. Am. J. Clin. Oncol. 1989, 12, 57–62, doi:10.1097/00000421‐ 198902000‐00014.
Perez, D.J.; Harvey, V.J.; Robinson, B.A.; Atkinson, C.H.; Dady, P.J.; Kirk, A.R.; Evans, B.D.; Chapman, P.J. A Randomized Comparison of Single‐Agent Doxorubicin and Epirubicin as First‐Line Cytotoxic Therapy in Advanced Breast Cancer. J. Clin. Oncol. 1991, 9, 2148–2152, doi:10.1200/JCO.1991.9.12.2148.
Wouters, K.A.; Kremer, L.C.M.; Miller, T.L.; Herman, E.H.; Lipshultz, S.E. Protecting against Anthracycline‐Induced Myocardial Damage: A Review of the Most Promising Strategies. Br. J. Haematol. 2005, 131, 561–578, doi:10.1111/j.1365‐ 2141.2005.05759.x.
Schettini, F.; Giuliano, M.; De Placido, S.; Arpino, G. Nab‐Paclitaxel for the Treatment of Triple‐Negative Breast Cancer: Rationale, Clinical Data and Future Perspectives. Cancer Treat. Rev. 2016, 50, 129–141, doi:10.1016/j.ctrv.2016.09.004.
van Dalen, E.C.; Michiels, E.M.; Caron, H.N.; Kremer, L.C. Different Anthracycline Derivates for Reducing Cardiotoxicity in Cancer Patients. Cochrane Database Syst. Rev. 2010, 2010, CD005006, doi:10.1002/14651858.CD005006.pub4.
Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies. Clin. Pharmacokinet. 2003, 42, 419–436, doi:10.2165/00003088‐200342050‐00002.
Giuliano, M.; Schettini, F.; Rognoni, C.; Milani, M.; Jerusalem, G.; Bachelot, T.; De Laurentiis, M.; Thomas, G.; De Placido, P.; Arpino, G.; et al. Endocrine Treatment versus Chemotherapy in Postmenopausal Women with Hormone Receptor‐Positive, HER2‐Negative, Metastatic Breast Cancer: A Systematic Review and Network Meta‐Analysis. Lancet Oncol. 2019, 20, 1360–1369, doi:10.1016/S1470‐2045(19)30420‐6.
Rakshitha, V.; Nalini, K.; Sahana, N.; Deepak, P.; Jayashree, N.; Mohith, N.; Divyashree, R. Comparison of Safety and Toxicity of Liposomal versus Conventional Doxorubicin: An Updated Review. Int. J. Basic Clin. Pharmacol. 2019, 8, 1453–1459, doi:10.18203/2319‐2003.ijbcp20192220.
Bulbake, U.; Doppalapudi, S.; Kommineni, N.; Khan, W. Liposomal Formulations in Clinical Use: An Updated Review. Phar-maceutics 2017, 9, 12, doi:10.3390/pharmaceutics9020012.
Rahman, A.; Carmichael, D.; Harris, M.; Roh, J.K. Comparative Pharmacokinetics of Free Doxorubicin and Doxorubicin En-trapped in Cardiolipin Liposomes. Cancer Res. 1986, 46, 2295–2299.
Swenson, C.E.; Perkins, W.R.; Roberts, P.; Janoff, A.S. Liposome Technology and the Development of Myocet™ (Liposomal Doxorubicin Citrate). Breast 2001, 10, 1–7, doi:10.1016/S0960‐9776(01)80001‐1.
Batist, G.; Ramakrishnan, G.; Rao, C.S.; Chandrasekharan, A.; Gutheil, J.; Guthrie, T.; Shah, P.; Khojasteh, A.; Nair, M.K.; Hoelzer, K.; et al. Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome‐Encapsulated Doxorubicin and Cy-clophosphamide Compared with Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer. J. Clin. Oncol. 2001, 19, 1444–1454, doi:10.1200/JCO.2001.19.5.1444.
Chan, S.; Davidson, N.; Juozaityte, E.; Erdkamp, F.; Pluzanska, A.; Azarnia, N.; Lee, L.W. Phase III Trial of Liposomal Doxoru-bicin and Cyclophosphamide Compared with Epirubicin and Cyclophosphamide as First‐Line Therapy for Metastatic Breast Cancer. Ann. Oncol. 2004, 15, 1527–1534, doi:10.1093/annonc/mdh393.
Harris, L.; Batist, G.; Belt, R.; Rovira, D.; Navari, R.; Azarnia, N.; Welles, L.; Winer, E.; TLC D‐99 Study Group. Liposome‐ Encapsulated Doxorubicin Compared with Conventional Doxorubicin in a Randomized Multicenter Trial as First‐Line Therapy of Metastatic Breast Carcinoma. Cancer 2002, 94, 25–36, doi:10.1002/cncr.10201.
French Epirubicin Study Group. Epirubicin‐Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose‐Intensity and Duration of Treatment. J. Clin. Oncol. 2000, 18, 3115–3124, doi:10.1200/JCO.2000.18.17.3115.
Xing, M.; Yan, F.; Yu, S.; Shen, P. Efficacy and Cardiotoxicity of Liposomal Doxorubicin‐Based Chemotherapy in Advanced Breast Cancer: A Meta‐Analysis of Ten Randomized Controlled Trials. PLoS ONE 2015, 10, e0133569, doi:10.1371/journal.pone.0133569.
Lorusso, V.; Giotta, F.; Bordonaro, R.; Maiello, E.; Del Prete, S.; Gebbia, V.; Filippelli, G.; Pisconti, S.; Cinieri, S.; Romito, S.; et al. Non‐Pegylated Liposome‐Encapsulated Doxorubicin Citrate plus Cyclophosphamide or Vinorelbine in Metastatic Breast Cancer Not Previously Treated with Chemotherapy: A Multicenter Phase III Study. Int. J. Oncol. 2014, 45, 2137–2142, doi:10.3892/ijo.2014.2604.
Schmid, P.; Krocker, J.; Kreienberg, R.; Klare, P.; Kittel, K.; Sommer, H.; Heinrich, G.; Steck, T.; Lichtenegger, W.; Elling, D.; et al. Non‐Pegylated Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer: Final Results of a Phase II Trial. Cancer Chemother. Pharmacol. 2009, 64, 401–406, doi:10.1007/s00280‐008‐0887‐3.
Fabi, A.; Ferretti, G.; Malaguti, P.; Gasparro, S.; Nisticò, C.; Arpino, G.; Papaldo, P.; Russillo, M.; Catania, G.; Schettini, F.; et al. Nanoparticle Albumin‐Bound Paclitaxel/Liposomal‐Encapsulated Doxorubicin in HER2‐Negative Metastatic Breast Cancer Pa-tients. Future Oncol. 2020, 16, 1629–1637, doi:10.2217/fon‐2019‐0742.
Rosati, M.S.; Raimondi, C.; Baciarello, G.; Grassi, P.; Giovannoni, S.; Petrelli, E.; Basile, M.L.; Girolami, M.; Di Seri, M.; Frati, L. Weekly Combination of Non‐Pegylated Liposomal Doxorubicin and Taxane in First‐Line Breast Cancer: WALT Trial (Phase I‐ II). Ann. Oncol. 2011, 22, 315–320, doi:10.1093/annonc/mdq392.
Curtit, E.; Nouyrigat, P.; Dohollou, N.; Levy, E.; Lortholary, A.; Gligorov, J.; Facchini, T.; Jaubert, D.; Maille, N.; Pivot, X.; et al. Myotax: A Phase II Trial of Docetaxel plus Non‐Pegylated Liposomal Doxorubicin as First‐Line Therapy of Metastatic Breast Cancer Previously Treated with Adjuvant Anthracyclines. Eur. J. Cancer 2011, 47, 2396–2402, doi:10.1016/j.ejca.2011.08.004.
Venturini, M.; Bighin, C.; Puglisi, F.; Olmeo, N.; Aitini, E.; Colucci, G.; Garrone, O.; Paccagnella, A.; Marini, G.; Crinò, L.; et al. A Multicentre Phase II Study of Non‐Pegylated Liposomal Doxorubicin in Combination with Trastuzumab and Docetaxel as First‐Line Therapy in Metastatic Breast Cancer. Breast 2010, 19, 333–338, doi:10.1016/j.breast.2010.01.018.
Lockman, P.R.; Mittapalli, R.K.; Taskar, K.S.; Rudraraju, V.; Gril, B.; Bohn, K.A.; Adkins, C.E.; Roberts, A.; Thorsheim, H.R.; Gaasch, J.A.; et al. Heterogeneous Blood‐Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer. Clin. Cancer Res. 2010, 16, 5664–5678, doi:10.1158/1078‐0432.CCR‐10‐1564.
Angeli, E.; Nguyen, T.T.; Janin, A.; Bousquet, G. How to Make Anticancer Drugs Cross the Blood‐Brain Barrier to Treat Brain Metastases. Int. J. Mol. Sci. 2019, 21, 22, doi:10.3390/ijms21010022.
Schmid, P.; Krocker, J.; Schulz, C.‐O.; Michniewicz, K.; Dieing, A.; Eggemann, H.; Heilmann, V.; Blohmer, J.‐U.; Sezer, O.; Elling, D.; et al. Primary Chemotherapy with Gemcitabine, Liposomal Doxorubicin and Docetaxel in Patients with Locally Advanced Breast Cancer: Results of a Phase I Trial. Anti‐Cancer Drugs 2005, 16, 21–29, doi:10.1097/00001813‐200501000‐00003.
Schmid, P.; Krocker, J.; Jehn, C.; Michniewicz, K.; Lehenbauer‐Dehm, S.; Eggemann, H.; Heilmann, V.; Kümmel, S.; Schulz, C.O.; Dieing, A.; et al. Primary Chemotherapy with Gemcitabine as Prolonged Infusion, Non‐Pegylated Liposomal Doxorubicin and Docetaxel in Patients with Early Breast Cancer: Final Results of a Phase II Trial. Ann. Oncol. 2005, 16, 1624–1631, doi:10.1093/annonc/mdi321.
Coltelli, L.; Fontana, A.; Lucchesi, S.; Ginocchi, L.; Bocci, G.; Filidei, M.; Scalese, M.; Arrighi, G.; Finale, C.; Marcucci, L.; et al. Cardiac Safety of Adjuvant Non‐Pegylated Liposomal Doxorubicin Combined with Cyclophosphamide and Followed by Paclitaxel in Older Breast Cancer Patients. Breast 2017, 31, 186–191, doi:10.1016/j.breast.2016.11.006.
Vici, P.; Pizzuti, L.; Gamucci, T.; Sergi, D.; Conti, F.; Zampa, G.; Del Medico, P.; De Vita, R.; Pozzi, M.; Botti, C.; et al. Non‐ Pegylated Liposomal Doxorubicin‐Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients. J. Cancer 2014, 5, 398–405, doi:10.7150/jca.9132.
Davidson, N.; Camburn, T.; Keary, I.; Houghton, D. Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study. Int. J. Breast Cancer 2014, 2014, 984067, doi:10.1155/2014/984067.
von Minckwitz, G.; Schneeweiss, A.; Loibl, S.; Salat, C.; Denkert, C.; Rezai, M.; Blohmer, J.U.; Jackisch, C.; Paepke, S.; Gerber, B.; et al. Neoadjuvant Carboplatin in Patients with Triple‐Negative and HER2‐Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial. Lancet Oncol. 2014, 15, 747–756, doi:10.1016/S1470‐2045(14)70160‐3.
Brain, E.G.C.; Mertens, C.; Girre, V.; Rousseau, F.; Blot, E.; Abadie, S.; Uwer, L.; Bourbouloux, E.; Van Praagh‐Doreau, I.; Mourey, L.; et al. Impact of Liposomal Doxorubicin‐Based Adjuvant Chemotherapy on Autonomy in Women over 70 with Hormone‐Receptor‐Negative Breast Carcinoma: A French Geriatric Oncology Group (GERICO) Phase II Multicentre Trial. Crit. Rev. Oncol. Hematol. 2011, 80, 160–170, doi:10.1016/j.critrevonc.2010.10.003.
Brain, E.; Girre, V.; Rollot, F.; Bonnetain, F.; Debled, M.; Lacroix, M.; Baffert, S.; Latouche, A.; Falandry, C.; Peyro Saint Paul, H.P.; et al. ASTER 70s: Benefit of Adjuvant Chemotherapy for Estrogen Receptor‐Positive HER2‐Negative Breast Cancer in Women over 70 According to Genomic Grade—A French GERICO/UCBG UNICANCER Multicenter Phase III Trial. JCO 2012, 30, TPS667, doi:10.1200/jco.2012.30.15_suppl.tps667.
Gradishar, W.J.; Moran, M.S.; Abraham, J.; Aft, R.; Agnese, D.; Allison, K.H.; Blair, S.L.; Burstein, H.J.; Dang, C.; Elias, A.D.; et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J. Natl. Compr. Cancer Netw. 2021, 19, 484–493, doi:10.6004/jnccn.2021.0023
Cardoso, F.; Paluch‐Shimon, S.; Senkus, E.; Curigliano, G.; Aapro, M.S.; André, F.; Barrios, C.H.; Bergh, J.; Bhattacharyya, G.S.; Biganzoli, L.; et al. 5th ESO‐ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5). Ann. Oncol. 2020, 31, 1623–1649, doi:10.1016/j.annonc.2020.09.010.
Cardoso, F.; Kyriakides, S.; Ohno, S.; Penault‐Llorca, F.; Poortmans, P.; Rubio, I.T.; Zackrisson, S.; Senkus, E. ESMO Guidelines Committee Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐Up. Ann. Oncol. 2019, 30, 1674, doi:10.1093/annonc/mdz189.
Gavilá, J.; Oliveira, M.; Pascual, T.; Perez‐Garcia, J.; Gonzàlez, X.; Canes, J.; Paré, L.; Calvo, I.; Ciruelos, E.; Muñoz, M.; et al. Safety, Activity, and Molecular Heterogeneity Following Neoadjuvant Non‐Pegylated Liposomal Doxorubicin, Paclitaxel, Trastuzumab, and Pertuzumab in HER2‐Positive Breast Cancer (Opti‐HER HEART): An Open‐Label, Single‐Group, Multicen-ter, Phase 2 Trial. BMC Med. 2019, 17, 8, doi:10.1186/s12916‐018‐1233‐1.
Antón, A.; Ruiz, A.; Plazaola, A.; Calvo, L.; Seguí, M.A.; Santaballa, A.; Muñoz, M.; Sánchez, P.; Miguel, A.; Carrasco, E.; et al. Phase II Clinical Trial of Liposomal‐Encapsulated Doxorubicin Citrate and Docetaxel, Associated with Trastuzumab, as Neo-adjuvant Treatment in Stages II and IIIA HER2‐Overexpressing Breast Cancer Patients. GEICAM 2003‐03 Study. Ann. Oncol. 2011, 22, 74–79, doi:10.1093/annonc/mdq317.
Saracchini, S.; Foltran, L.; Tuccia, F.; Bassini, A.; Sulfaro, S.; Micheli, E.; Del Conte, A.; Bertola, M.; Gion, M.; Lorenzon, M.; et al. Phase II Study of Liposome‐Encapsulated Doxorubicin plus Cyclophosphamide, Followed by Sequential Trastuzumab plus Docetaxel as Primary Systemic Therapy for Breast Cancer Patients with HER2 Overexpression or Amplification. Breast 2013, 22, 1101–1107, doi:10.1016/j.breast.2013.09.001.
Tarantino, P.; Tolaney, S.M.; Harbeck, N.; Cortes, J.; Curigliano, G. Anthracyclines for Human Epidermal Growth Factor Receptor 2‐Positive Breast Cancer: Are We Ready to Let Them Go? J. Clin. Oncol. 2021, JCO2101059, doi:10.1200/JCO.21.01059.
Amadori, D.; Milandri, C.; Comella, G.; Saracchini, S.; Salvagni, S.; Barone, C.; Bordonaro, R.; Gebbia, V.; Barbato, A.; Serra, P.; et al. A Phase I/II Trial of Non‐Pegylated Liposomal Doxorubicin, Docetaxel and Trastuzumab as First‐Line Treatment in HER‐ 2‐Positive Locally Advanced or Metastatic Breast Cancer. Eur. J. Cancer 2011, 47, 2091–2098, doi:10.1016/j.ejca.2011.05.005.
Cortes, J.; Di Cosimo, S.; Climent, M.A.; Cortés‐Funes, H.; Lluch, A.; Gascón, P.; Mayordomo, J.I.; Gil, M.; Benavides, M.; Cirera, L.; et al. Nonpegylated Liposomal Doxorubicin (TLC‐D99), Paclitaxel, and Trastuzumab in HER‐2‐Overexpressing Breast Can-cer: A Multicenter Phase I/II Study. Clin. Cancer Res. 2009, 15, 307–314, doi:10.1158/1078‐0432.CCR‐08‐1113.
Baselga, J.; Manikhas, A.; Cortés, J.; Llombart, A.; Roman, L.; Semiglazov, V.F.; Byakhov, M.; Lokanatha, D.; Forenza, S.; Gold-farb, R.H.; et al. Phase III Trial of Nonpegylated Liposomal Doxorubicin in Combination with Trastuzumab and Paclitaxel in HER2‐Positive Metastatic Breast Cancer. Ann. Oncol. 2014, 25, 592–598, doi:10.1093/annonc/mdt543.
Baselga, J.; Cortés, J.; Kim, S.‐B.; Im, S.‐A.; Hegg, R.; Im, Y.‐H.; Roman, L.; Pedrini, J.L.; Pienkowski, T.; Knott, A.; et al. Per-tuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N. Engl. J. Med. 2012, 366, 109–119, doi:10.1056/NEJMoa1113216.
Schettini, F.; Conte, B.; Buono, G.; De Placido, P.; Parola, S.; Griguolo, G.; Fabi, A.; Bighin, C.; Riccardi, F.; Cianniello, D.; et al. T‐DM1 versus Pertuzumab, Trastuzumab and a Taxane as First‐Line Therapy of Early‐Relapsed HER2‐Positive Metastatic Breast Cancer: An Italian Multicenter Observational Study. ESMO Open 2021, 6, 100099, doi:10.1016/j.esmoop.2021.100099.
Verma, S.; Miles, D.; Gianni, L.; Krop, I.E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D.‐Y.; Diéras, V.; Guardino, E.; et al. Trastuzumab Emtansine for HER2‐Positive Advanced Breast Cancer. N. Engl. J. Med. 2012, 367, 1783–1791, doi:10.1056/NEJMoa1209124.
López‐Miranda, E.; Pérez‐García, J.M.; Di Cosimo, S.; Brain, E.; Ravnik, M.; Escrivá‐de‐Romaní, S.; Vidal, M.; Gligorov, J.; Borštnar, S.; Calabuig, L.; et al. Trastuzumab Emtansine Plus Non‐Pegylated Liposomal Doxorubicin in HER2‐Positive Meta-static Breast Cancer (Thelma): A Single‐Arm, Multicenter, Phase Ib Trial. Cancers 2020, 12, 3509, doi:10.3390/cancers12123509.
Moy, B.; Rumble, R.B.; Come, S.E.; Davidson, N.E.; Di Leo, A.; Gralow, J.R.; Hortobagyi, G.N.; Yee, D.; Smith, I.E.; Chavez‐ MacGregor, M.; et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2‐ Negative Metastatic Breast Cancer That is Either Endocrine‐Pretreated or Hormone Receptor‐Negative: ASCO Guideline Up-date. J. Clin. Oncol. 2021, epub ahead of print, doi:10.1200/JCO.21.01374.
Schettini, F.; Giudici, F.; Bernocchi, O.; Sirico, M.; Corona, S.P.; Giuliano, M.; Locci, M.; Paris, I.; Scambia, G.; De Placido, S.; et al. Poly (ADP‐Ribose) Polymerase Inhibitors in Solid Tumours: Systematic Review and Meta‐Analysis. Eur. J. Cancer 2021, 149, 134–152, doi:10.1016/j.ejca.2021.02.035.
Militello, A.M.; Zielli, T.; Boggiani, D.; Michiara, M.; Naldi, N.; Bortesi, B.; Zanelli, P.; Uliana, V.; Giuliotti, S.; Musolino, A. Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA‐Mutated, Estrogen Receptor‐Positive Breast Cancers: Case Report and Literature Review. Front. Oncol. 2019, 9, 759, doi:10.3389/fonc.2019.00759.
Schettini, F.; Giudici, F.; Giuliano, M.; Cristofanilli, M.; Arpino, G.; Del Mastro, L.; Puglisi, F.; De Placido, S.; Paris, I.; De Placido, P.; et al. Overall Survival of CDK4/6‐Inhibitors‐Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta‐Analysis. J. Natl. Cancer Inst. 2020, 112, 1089–1097, doi:10.1093/jnci/djaa071.
Nanni, O.; Amadori, D.; De Censi, A.; Rocca, A.; Freschi, A.; Bologna, A.; Gianni, L.; Rosetti, F.; Amaducci, L.; Cavanna, L.; et al. Metformin plus Chemotherapy versus Chemotherapy Alone in the First‐Line Treatment of HER2‐Negative Metastatic Breast Cancer. The MYME Randomized, Phase 2 Clinical Trial. Breast Cancer Res. Treat. 2019, 174, 433–442, doi:10.1007/s10549‐018‐ 05070‐2.
Mbuagbaw, L.; Rochwerg, B.; Jaeschke, R.; Heels‐Andsell, D.; Alhazzani, W.; Thabane, L.; Guyatt, G.H. Approaches to Inter-preting and Choosing the Best Treatments in Network Meta‐Analyses. Syst. Rev. 2017, 6, 79, doi:10.1186/s13643‐017‐0473‐z.
Gradishar, W.J.; Krasnojon, D.; Cheporov, S.; Makhson, A.N.; Manikhas, G.M.; Clawson, A.; Bhar, P. Significantly Longer Pro-gression‐Free Survival with Nab‐Paclitaxel Compared with Docetaxel as First‐Line Therapy for Metastatic Breast Cancer. J. Clin. Oncol. 2009, 27, 3611–3619, doi:10.1200/JCO.2008.18.5397.
Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O’Shaughnessy, J. Phase III Trial of Nanoparticle Albumin‐Bound Paclitaxel Compared with Polyethylated Castor Oil‐Based Paclitaxel in Women with Breast Can-cer. J. Clin. Oncol. 2005, 23, 7794–7803, doi:10.1200/JCO.2005.04.937.
Gradishar, W.J.; Krasnojon, D.; Cheporov, S.; Makhson, A.N.; Manikhas, G.M.; Clawson, A.; Bhar, P.; McGuire, J.R.; Iglesias, J. Phase II Trial of Nab‐Paclitaxel Compared with Docetaxel as First‐Line Chemotherapy in Patients with Metastatic Breast Cancer: Final Analysis of Overall Survival. Clin. Breast Cancer 2012, 12, 313–321, doi:10.1016/j.clbc.2012.05.001.
Rigacci, L.; Annibali, O.; Kovalchuk, S.; Bonifacio, E.; Pregnolato, F.; Angrilli, F.; Vitolo, U.; Pozzi, S.; Broggi, S.; Luminari, S.; et al. Nonpeghylated Liposomal Doxorubicin Combination Regimen (R‐COMP) for the Treatment of Lymphoma Patients with Advanced Age or Cardiac Comorbidity. Hematol. Oncol. 2020, 38, 478–486, doi:10.1002/hon.2764.
Luminari, S.; Viel, E.; Ferreri, A.J.M.; Zaja, F.; Chimienti, E.; Musuraca, G.; Tucci, A.; Balzarotti, M.; Tani, M.; Salvi, F.; et al. Nonpegylated Liposomal Doxorubicin Combination Regimen in Patients with Diffuse Large B‐Cell Lymphoma and Cardiac Comorbidity. Results of the HEART01 Phase II Trial Conducted by the Fondazione Italiana Linfomi. Hematol. Oncol. 2018, 36, 68–75, doi:10.1002/hon.2425.
Szmit, S.; Grela‐Wojewoda, A.; Talerczyk, M.; Kufel‐Grabowska, J.; Streb, J.; Smok‐Kalwat, J.; Iżycki, D.; Chmielowska, E.; Wilk, M.; Sosnowska‐Pasiarska, B. Predictors of New‐Onset Heart Failure and Overall Survival in Metastatic Breast Cancer Patients Treated with Liposomal Doxorubicin. Sci. Rep. 2020, 10, 18481, doi:10.1038/s41598‐020‐75614‐4.
Szmit, S.; Jurczak, W.; Zaucha, J.M.; Długosz‐Danecka, M.; Sosnowska‐Pasiarska, B.; Chmielowska, E.; Joks, M.; Drozd‐ Sokołowska, J.; Knopińska‐Posłuszny, W.; Spychałowicz, W.; et al. Acute Decompensated Heart Failure as a Reason of Prema-ture Chemotherapy Discontinuation May Be Independent of a Lifetime Doxorubicin Dose in Lymphoma Patients with Cardiovascular Disorders. Int. J. Cardiol. 2017, 235, 147–153, doi:10.1016/j.ijcard.2017.02.073.
Aapro, M.; Bernard‐Marty, C.; Brain, E.G.; Batist, G.; Erdkamp, F.; Krzemieniecki, K.; Leonard, R.; Lluch, A.; Monfardini, S.; Ryberg, M.; et al. Anthracycline cardiotoxicity in the elderly cancer patient: A SIOG expert position paper. Ann. Oncol. 2011, 22, 257–267, doi:10.1093/annonc/mdq609.
European Commission Myocet’s Summary of Product Characteristics. Annex I. Available online: https://ec.eu-ropa.eu/health/documents/community‐register/2015/20150127130862/anx_130862_en.pdf (accessed on 31 August 2021)
Seicean, S.; Seicean, A.; Alan, N.; Plana, J.C.; Budd, G.T.; Marwick, T.H. Cardioprotective Effect of β‐Adrenoceptor Blockade in Patients with Breast Cancer Undergoing Chemotherapy: Follow‐up Study of Heart Failure. Circ. Heart Fail. 2013, 6, 420–426, doi:10.1161/CIRCHEARTFAILURE.112.000055.
